The efficacy and safety of baxdrostat in treating hypertension
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on April 24th, 2023
|
Aldosterone can increase the rate of sodium reabsorption and water retention; thus, it can enhance risk of hypertension. Thus, in order to manage the condition, aldosterone synthase has been an ideal pharmaceutical target. CinCor Pharma had funded a study to examine the effect of baxdrostat, a highly selective aldosterone synthase inhibitor, on managing hypertension.
The phase 2 clinical trial included 248 patients who have been treated with at least 3 different types of antihypertensive medications without significant beneficial results. These patients were randomly assigned to receive a daily pill containing either placebo or 3 different dosages of baxdrostat: 0.5 mg, 1.0 mg, and 2.0 mg. After 12 weeks, the researchers found that the average systolic blood pressure of those who took 2.0 mg of baxdrostat was 11.0 mmHg lower than those who were in the control group; the difference was 8.1 mmHg between the 1.0 mg baxdrostat and placebo group. In terms of safety, between 1 to 3 % of those who received baxdrostat reported mild hyperkalemia; in spite of that, there was no significant difference in the frequency of adverse events between the 4 groups. Thus, the effectiveness of baxdrostat can be investigated in a larger and longer phase 3 clinical trial.
The phase 2 clinical trial included 248 patients who have been treated with at least 3 different types of antihypertensive medications without significant beneficial results. These patients were randomly assigned to receive a daily pill containing either placebo or 3 different dosages of baxdrostat: 0.5 mg, 1.0 mg, and 2.0 mg. After 12 weeks, the researchers found that the average systolic blood pressure of those who took 2.0 mg of baxdrostat was 11.0 mmHg lower than those who were in the control group; the difference was 8.1 mmHg between the 1.0 mg baxdrostat and placebo group. In terms of safety, between 1 to 3 % of those who received baxdrostat reported mild hyperkalemia; in spite of that, there was no significant difference in the frequency of adverse events between the 4 groups. Thus, the effectiveness of baxdrostat can be investigated in a larger and longer phase 3 clinical trial.